None of the BRAFi Type I 1/2 and MEK1/2i MSS correlated with tumor progression in the untreated group, allowing to suggest that the signatures are not affected by a confounding effect driven by the spontaneous evolution of the tumor (Supplementary Fig. S9a). Here, MAP2K1 is linked to neoplasm.